⌘K

16:05:18·531d

13D/GFilingvia Quantisnow

Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

ByQuantisnow·Wall Street's wire, on your screen.

ELVN· Enliven Therapeutics Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

ELVN
Enliven Therapeutics Inc.
Health Care

Recent analyst ratings

Jun 16UpdateGoldman$37.00
Dec 13UpdateBTIG Research$42.00
Sep 9UpdateH.C. Wainwright$37.00
Jun 11UpdateRobert W. Baird$32.00
Apr 9UpdateMizuho$34.00
Mar 29UpdateJefferies$27.00

Related

SEC2d
SEC Form DEFA14A filed by Enliven Therapeutics Inc.
SEC2d
SEC Form DEF 14A filed by Enliven Therapeutics Inc.
INSIDER8d
SEC Form 4 filed by Collins Helen Louise
SEC14d
SEC Form PRE 14A filed by Enliven Therapeutics Inc.
INSIDER33d
SEC Form 4 filed by Collins Helen Louise
INSIDER41d
SEC Form 4 filed by Collins Helen Louise
INSIDER49d
SEC Form 4 filed by Enliven Therapeutics Inc.
INSIDER50d
CHIEF FINANCIAL OFFICER Hohl Benjamin sold $295,839 worth of shares (10,000 units at $29.58), decreasing direct ownership by 16% to 51,000 units (SEC Form 4)